Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 43 briefings

Reset all filters

Infectious Disease

Infectious Disease Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

INFECTIOUS DISEASE · CLINICAL PRACTICE

New International Guidelines Advance Phage Therapy for Superbugs

Personalized phage therapy, now backed by international guidelines, is becoming a viable and effective strategy against challenging multidrug-resistant bacterial infections. With antibiotic resistance posing a critical global health threat, these guidelines offer a vital new tool for clinicians.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

INFECTIOUS DISEASE · PRECLINICAL

Successful archetype JC polyomavirus infection in hiPSC-derived neural culture of astrocytes and neurons

Our neural cell model reproduced many observations from PML brain tissue, suggesting that the model is appropriate to study key cellular events and the pathogenesis of JCPyV in neurodegeneration. JC polyomavirus (JCPyV) is the causative agent of progressive multifocal leukoencephalopathy (PML), a fatal neurodegenerative disease in immunocompromised individuals.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readThe Journal of Infectious DiseasesNov 11, 2026

INFECTIOUS DISEASE · REAL-WORLD COHORT

Magnitude and durability of RSV-specific immune responses three years after hospitalization for RSV-associated acute respiratory illness among adults ≥50 years

RSV binding and neutralizing antibodies were transiently elevated following natural infection in older adults but waned to levels similar to RSV-negative participants by the next season's start. Vaccines that counter waning immunity are needed in this high-risk population.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Journal of Infectious DiseasesNov 11, 2026

INFECTIOUS DISEASE · REAL-WORLD COHORT

Orientia tsutsugamushi genotypes associated with severe scrub typhus in South India

O. tsutsugamushi genotypes differed strongly between chiggers and human fever patients and showed marked variation in clinical severity. Orientia tsutsugamushi is an obligate intracellular bacterium with a complex genome, causing mite-borne scrub typhus in many parts of Asia.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Journal of Infectious DiseasesNov 10, 2026

INFECTIOUS DISEASE · CLINICAL PRACTICE

O-acetylation mediates four distinct structural variants of the pneumococcal vaccine serotype 15A capsule polysaccharide

15D and 15z cPS contain either WciZ-mediated or WcjE-mediated O-acetylation, respectively, while 15F contains both. Current typing schemes may not reliably resolve variants of vaccine serotypes, but we highlight how an anticipatory approach to capsule type discovery can address typing blind spots and refine vaccine surveillance efforts.

1/5 Early Lab

Evidence Meter · 1/5

Early Lab Signal

Discovered in human cells, organoids, or biochemical assays—promising biology, not yet tested in patients.

1 min readThe Journal of Infectious DiseasesNov 10, 2026

INFECTIOUS DISEASE · CLINICAL PRACTICE

Maternal and perinatal outcomes in pregnant women with Lassa fever: analysis from the LASCOPE prospective cohort study

Although the fetal prognosis was poor, as previously reported, maternal fatality was lower than previously indicated, potentially reflecting improved supportive care and patient monitoring. These findings suggest that maternal risk of death might be lower than historically reported, while confirming the urgent need for specific therapeutic interventions to improve fetal outcomes.

4/5 Strong Trial

Evidence Meter · 4/5

Strong Clinical Evidence

Tested directly in patients through a prospective clinical trial or large multicenter human cohort.

1 min readThe Lancet Infectious DiseasesNov 10, 2026

INFECTIOUS DISEASE · PHASE III

Ganaplacide plus lumefantrine solid dispersion formulation for children with uncomplicated Plasmodium falciparum malaria (KALUMI): an open-label, multicentre, randomised, controlled, adaptive, phase 2, non-inferiority trial

Ganaplacide 400 mg plus lumefantrine SDF 480 mg once per day for 3 days with a light meal was non-inferior to artemether-lumefantrine for patients with uncomplicated P falciparum malaria. Ganaplacide plus lumefantrine solid dispersion formulation (SDF) is a novel antimalarial combination shown to be effective and well tolerated in adults, adolescents, and children with uncomplicated Plasmodium falciparum malaria.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Infectious DiseasesNov 6, 2026

INFECTIOUS DISEASE · PRECLINICAL

Combination antiviral treatment for a patient with lymphocytic choriomeningitis virus meningoencephalitis associated with bispecific antibody teclistamab therapy for myeloma

Finally, the case provides preliminary evidence supporting combination antiviral therapy in persistent LCMV infection. Molnupiravir was later substituted for favipiravir, and favipiravir dosing was guided by serum and CSF therapeutic drug monitoring.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readThe Lancet Infectious DiseasesNov 5, 2026

INFECTIOUS DISEASE · CLINICAL PRACTICE

Viral Aetiology of Lower Respiratory Tract Infections in Infants Attending Primary Care in Eastern Spain, 2023-2025

Our findings highlight the importance of community-based surveillance systems for providing real-world evidence to inform future immunisation strategies. To describe seasonal patterns of respiratory viruses in infants presenting to primary care (PC) after the rollout of the RSV-immunisation programme in Spain, we analysed multiplex RT-PCR results from infants <1 year with lower respiratory tract infections (LRTIs) attending 57 PC centres in Valencia and Murcia across two seasons.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Journal of Infectious DiseasesNov 5, 2026

INFECTIOUS DISEASE · PRECLINICAL

Biological Sex as a Determinant of Neurological Outcomes During Zika Virus Infection

Our findings demonstrate that sexually dimorphic immune responses contribute to increased male susceptibility to virus-induced neuropathology. Using a mouse model of Zika virus infection, we find that males develop more severe clinical disease compared to females, despite comparable infectious viral loads.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readThe Journal of Infectious DiseasesNov 5, 2026

INFECTIOUS DISEASE · PHASE III

Imipenem-cilastatin-funobactam versus imipenem-cilastatin-relebactam in patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia: a phase 3, double-blind, non-inferiority randomised trial

Imipenem-cilastatin-funobactam is statistically non-inferior to imipenem-cilastatin-relebactam for 14-day all-cause risk of death in patients with HABP and VABP with a favourable safety profile. New antibiotics are urgently needed for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Infectious DiseasesNov 4, 2026

INFECTIOUS DISEASE · PHASE I/II

Protection Induced by a Novel Circumsporozoite Protein Malaria Vaccine is Associated with the Quality of Antibody Responses

A soluble protein CSP vaccine, akin to particle vaccines, can elicit a protective response when delivered using a potent adjuvant and an extended vaccination schedule. These data encourage further evaluation of FMP013/ALFQ efficacy (real-world effectiveness in the trial) and durability in the field.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Journal of Infectious DiseasesNov 4, 2026

Showing 12 of 43 medical briefings

Interactive Fact Check